Journals / Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi / 2021 / Cilt: 26 - Sayı: 2

Double-edged Knife: Can Colistin Nephrotoxicity be Prevented with High Doses of Vitamin C?

İki Ucu Keskin Bıçak: Kolistin Yüksek Doz C Vitamini ile Nefrotoksisite Önlenebilir mi?

Pages
303–310
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However further research is needed with more patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: In this study, it was aimed to determine the risk factors for developing acute kidney injury (AKI) and effects of ascorbic acid on the development of nephrotoxicity in patients receiving systemic colistin sodium therapy.
📊
Key Findings & Data:Materials and Methods: We retrospectively reviewed records of cases who were treated with systemic colistin sodium and did not have any known renal disease in our hospital between the years of 2014 and 2019.
💡
Conclusion & Impact:However further research is needed with more patients.
🔬Design:Review & Systematic Survey
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Introduction: In this study, it was aimed to determine the risk factors for developing acute kidney injury (AKI) and effects of ascorbic acid on the development of nephrotoxicity in patients receiving systemic colistin sodium therapy. Materials and Methods: We retrospectively reviewed records of cases who were treated with systemic colistin sodium and did not have any known renal disease in our hospital between the years of 2014 and 2019. The demographic characteristics, indications for systemic colistin, other antibiotics applied and nephrotoxic drugs, vasopressor necessity, daily creatinine values, development of acute kidney injury, and ascorbic acid use were evaluated. Acute kidney injury was assessed according to KDIGO 2017. Results: Sixty-six patients were included in the study. In addition to colistin therapy, 33 cases who received at least three grams of ascorbic acid per day and 33 cases who received only colistin therapy were evaluated retrospectively. Acute kidney injury developed in 12 (36.4%) of those receiving ascorbic acid and 15 (45.5%) in those not receiving ascorbic acid (p= 0.617). Acute kidney injury developed in 9.1 ± 5.9 days in ascorbic acid patients and 7.1 ± 4.4 days in non-ascorbic acid patients (p= 0.314). The rate of septic shock development was significantly lower in patients receiving ascorbic acid (30.3% vs 57.6%, p= 0.046). Advanced age (p= 0.005), sepsis (p= 0.046), and underlying cardiac disease (p= 0.01) were found to be statistically significant in terms of the development of nephrotoxicity. Conclusion: Although no statistically significant effect of ascorbic acid using on the development of colistin-related nephrotoxicity was determined in our study, we think that high dose vitamin C may be beneficial in selected patient groups in terms of the fact that AKI is seen less in the group using ascorbic acid, does not have serious side effects and has a positive effect on preventing from septic shock. However further research is needed with more patients.

Özet

Giriş: Bu çalışmada sistemik kolistin sodyum tedavisi alan hastalarda akut böbrek hasarı (ABH) gelişimi için risk faktörlerinin ve askorbik asidin nefrotoksisite gelişimi üzerine olan etkisinin araştırılması amaçlanmıştır. Materyal ve Metod: Hastanemizde 2014-2019 yılları arasında yatarak sistemik kolistin sodyum tedavisi alan ve tedavi başlangıcında böbrek fonksiyon testleri normal olan hastalar retrospektif olarak değerlendirilmiştir. Hastaların demografik bilgileri, sistemik kolistin endikasyonları, ek antibiyotikler ve nefrotoksik ilaçlar, vazopressör gerekliliği, günlük kreatinin değerleri, akut böbrek hasarı gelişimi, askorbik asit tedavisi alıp almadığı kaydedilmiştir. Akut böbrek hasarı Kidney Disease Improving Global Outcomes (KDIGO) 2017 rehberine göre değerlendirilmiştir. Bulgular: Çalışmaya dahil edilen toplam 66 hastadan sistemik kolistin ile birlikte günde üç gram askorbik asit alan 33 hasta ile sadece sistemik kolistin tedavisi alan 33 hasta retrospektif olarak değerlendirilmiştir. Askorbik asit alan grupta olguların 12’sinde (%36.4) akut böbrek hasarı gelişirken, almayanların 15’inde (%45.5) gelişmiştir (p= 0.617). Askorbik asit alan hastalarda akut böbrek hasarı 9.1 ± 5.9 günde gelişirken, almayanlarda 7.1 ± 4.4 günde gelişmiştir (p= 0.314). Askorbik asit alan hastalarda septik şok gelişme oranı anlamlı olarak daha düşük bulunmuştur (%30.3 vs %57.6, p= 0.046). İleri yaş (p= 0.005), sepsis varlığı (p= 0.046) ve kardiyak hastalık varlığı (p= 0.01) nefrotoksisite gelişimi açısından istatistiksel olarak anlamlı bulunmuştur. Sonuç: Çalışmamızda askorbik asit kullanımının kolistin ile ilişkili nefrotoksisite gelişimi üzerine istatistiksel olarak anlamlı etkisi saptanamamış olsa da kullanılan grupta ABH’ın daha az görülmesi, ciddi yan etkisi olmaması ve septik şokun önlenmesinde olumlu etkisi açısından yüksek doz C vitamininin seçilmiş hasta gruplarında faydalı olabileceğini düşünmekteyiz. Ancak bu konuda daha fazla hasta sayısı ile yeni araştırmalara gereksinim olduğu açıktır.

🔖

Cite This Article

YILDIRIM, Ç., PULLUKÇU, H., TAŞBAKAN, M. I., ERDEM, H. A., EKREN, P. K., AKYOL, D., BACAKOĞLU, F. (2022). Double-edged Knife: Can Colistin Nephrotoxicity be Prevented with High Doses of Vitamin C?. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, Cilt: 26 - Sayı: 2, 303–310. https://ajindex.com/articles/517077

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clinical infectious diseases 2005;40(9):1333-41
  2. Conly JM, Johnston BL. Colistin: the phoenix arises. Canadian Journal of Infectious Diseases and Medical Microbiology 2006;17
  3. Wallaces J, Li J, Rayner CR, Coulthard K, Nation RL. Stability of Colistin Methanesulfonate in Pharmaceutical Products and Solutions for Administration to Patients. Antimicrobial Agents and Chemotherapy 2008;52(9),3047-51
  4. Yapa SWS, Li J, Porter CHJ, Nation RL, Patel K, Mcintosh MP. Population pharmacokinetics of colistin methanesulfonate in rats: Achieving sustained lung concentrations of colistin for targeting tespiratory infections. Antimicrobial Agents and Chemotherapy 2013;57(10),5087-5095
  5. Gantenbein, Urs Leo. “Poison and its dose: Paracelsus on toxicology.” Toxicology in the middle ages and renaissance. Academic Press 2017:1-10
  6. Spapen H, Jacobs R, Gorp V, Troubleyn J, Honoré P. Renal and neurological side effects of colistin in critically ill patients. Annals of Intensive Care 2011,1:14 7. Dalfino L, Puntillo F, Ondok M, Mosca A, Monno R, Coppolecchia S, Spada M, Bruno F, Brienza N. Colistin-associated acute kidney injury in severely ill patients: A step toward a better renal care? A prospective cohort study. Clin Infect Dis 2015;61(12):1771-7
  7. Ozyilmaz E, Ebinc FA, Derici U, Gulbahar O, Goktas G, Elmas C, Oguzulgen IK, Sindel S. Could nephrotoxicity due to colistin be ameliorated with the use of N-acetylcysteine? Intensive Care Med 2011;37(1):141-6 9. Ceylan B, Ozansoy M, Kılıç Ü, Yozgat Y, Ercan Ç, Yıldız P, Aslan T. N-acetylcysteine suppresses colistimethate sodium- induced nephrotoxicity via activation of SOD2, eNOS, and MMP3 protein expressions. Ren Fail 2018;40(1):423- 34 10. Clinical Practice Guideline for Acute Kidney Injury. Official Journal of the International Society of Nephrology 2012;2(1
  8. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Crit Care Med 2013;41(2):580-637 12. Bergen PJ., Landersdorfer CB., Zhang J, Zhao M, Lee HJ, Nation RL, Li J. Pharmacokinetics and pharmacodynamics of ‘old’polymyxins: what is new? Diagnostic microbiology and infectious disease 2012;74(3):213-23
  9. Coşkun B, Azap A, Yılmaz G, Ayhan M, Sarıcaoğlu EM. Assessment of colistin treatment in multidrug-resistant Gram-negative bacterial infections. Klim